The present disclosure provides an assay device and associated method(s) to facilitate the determination of risk of a subject to develop severe forms of SARS-CoV2 infection. Said determination of risk or genetic predisposition to severe forms of SARS-CoV2 infection employing the assay device and associated method(s)...

The present disclosure provides means to facilitate the detection of SARS-CoV-2 infection. The 10 present disclosure provides CRISPR sgRNA sequence(s) that allows detection SARS-CoV-2 infection. Said sequence(s) of the present disclosure further facilitate identification and differentiation between variants of S...

The invention provides a guide RNA [gRNA], a kit, a composition, and a method for detecting genetic variations such as Sickle Cell Anemia (SCA) and identifying carriers through an optimized point-of-care CRISPR-based assay. The gRNA detects SCA-specific nucleotide changes using distinct mixes for Haemoglobin A (HbA)...